🧬 "Undruggable" No More: New Pill Nearly Doubles Survival in Advanced Pancreatic Cancer

For decades, pancreatic cancer has been one of medicine's most hopeless diagnoses. More than 90% of cases are driven by mutations in a gene called KRAS — a protein scientists long labeled "undruggable" because its surface is so unnaturally smooth that no drug could latch onto it. That era just ended.

A new oral drug called daraxonrasib takes a brilliantly indirect approach: instead of trying to bind KRAS directly, it grabs onto a helper molecule called cyclophilin A inside the cell. That drug-protein complex then clamps onto active KRAS and physically shuts it down, silencing the "grow forever" signal at its source. The approach is so novel that it targets multiple mutant forms of RAS at once, making resistance much harder for the cancer to develop.

In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had already been through prior treatment, the results were striking. Patients on daraxonrasib lived a median of 13.2 months compared to just 6.7 months on standard chemotherapy — nearly double. The drug reduced the overall risk of death by 60%. Results were presented by Revolution Medicines and published in the New England Journal of Medicine.

Side effects are real — a prominent skin rash affected 86% of patients, along with mouth sores, diarrhea, and nausea — but patients on daraxonrasib were far less likely to abandon treatment than those on chemo, and reported better quality of life with less pain.

— Median overall survival: 13.2 months (daraxonrasib) vs 6.7 months (chemotherapy)
— 60% reduction in risk of death
— Once-daily pill — no infusions, no hospital visits
— Works against multiple RAS mutations simultaneously, limiting resistance
— Lower treatment discontinuation rate and improved quality of life vs chemo

"For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible. That narrative is rapidly changing." — Dr. Christopher Lieu, Professor of Medical Oncology, University of Colorado

Why it matters: Pancreatic cancer kills 97% of patients with metastatic disease within five years. Chemotherapy has been our only real tool — a blunt instrument with brutal side effects. Daraxonrasib is the first therapy to go after the genetic engine of the disease itself. If approved, it would be the most significant advance in pancreatic cancer treatment in a generation, and the platform — hijacking cyclophilin A to reach "undruggable" targets — could open doors for dozens of other cancers driven by RAS mutations.

📄 NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2605555
📖 ScienceDaily: https://www.sciencedaily.com/releases/2026/06/260604044247.htm
📖 The Conversation: https://theconversation.com/breakthrough-drug-nearly-doubles-survival-with-advanced-pancreatic-cancer-an-oncologist-explains-how-daraxonrasib-overcame-an-undruggable-disease-283647

#PancreaticCancer #KRAS #CancerResearch #MedicalBreakthrough #science